| 3.215 -0.735 (-18.61%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.86 |
1-year : | 8.95 |
| Resists | First : | 5.87 |
Second : | 7.67 |
| Pivot price | 5.82 |
|||
| Supports | First : | 2.97 |
Second : | 2.47 |
| MAs | MA(5) : | 3.86 |
MA(20) : | 6.13 |
| MA(100) : | 8.12 |
MA(250) : | 6.27 |
|
| MACD | MACD : | -1 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 4.7 |
D(3) : | 6.6 |
| RSI | RSI(14): 23.3 |
|||
| 52-week | High : | 13.6 | Low : | 2.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OMER ] has closed above bottom band by 5.0%. Bollinger Bands are 120.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.94 - 3.96 | 3.96 - 3.98 |
| Low: | 2.93 - 2.95 | 2.95 - 2.97 |
| Close: | 3.18 - 3.22 | 3.22 - 3.24 |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Fri, 16 May 2025
Omeros Corp. Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Fri, 16 May 2025
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Fri, 16 May 2025
Omeros: Q1 Earnings Snapshot - CT Insider
Fri, 16 May 2025
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... - Yahoo Finance
Fri, 16 May 2025
Omeros Corporation Reports Q1 2025 Financial Results - TipRanks
Thu, 15 May 2025
Omeros (OMER) Streamlines Debt, Preps for Narsoplimab Launch - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 46.1 (%) |
| Shares Short | 9,170 (K) |
| Shares Short P.Month | 9,330 (K) |
| EPS | -3.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.23 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -149 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | -1.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|